Tokyo, April 1 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000060141) titled 'Diagnostic accuracy of FGFR2 gene alterations in endoscopic transpapillary biopsy specimens of hilar cholangiocarcinoma' on April 1.
Study Type:
Observational
Primary Sponsor:
Institute - Nagoya University
Condition:
Condition - Perihilar cholangiocarcinoma
Classification by malignancy - Malignancy
Genomic information - YES
Objective:
Narrative objectives1 - We evaluated the concordance rate of FGFR2 mutation detection between transpapillary biopsy specimens and surgical specimens in patients with perihilar cholangiocarcinoma.
Basic objectives2 - Others
Eligibility:
Age-lower limit - 18
years-old
<=
Age-upper limit - Not applicable
Gender - Male and Female
Key inclusion criteria - Patients who were diagnosed with cancer by preoperative bile duct biopsy and subsequently underwent surgery at Nagoya University Hospital between January 1, 2015, and July 31, 2025, and who were pathologically confirmed to have perihilar cholangiocarcinoma were included.
Key exclusion criteria - Patients who received preoperative chemotherapy.
Target Size - 100
Recruitment Status:
Recruitment status - Preinitiation
Date of protocol fixation - 2025 Year 12 Month 19 Day
Anticipated trial start date - 2026 Year 04 Month 01 Day
Last follow-up date - 2027 Year 03 Month 31 Day
To know more, visit https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000068786
Disclaimer: Curated by HT Syndication.
